Prospective Study
Copyright ©The Author(s) 2017.
World J Crit Care Med. Feb 4, 2017; 6(1): 74-78
Published online Feb 4, 2017. doi: 10.5492/wjccm.v6.i1.74
Table 1 Baseline characteristics of the patients (n = 15)
Age (yr)57 (IQR = 22)
Gender12 men, 3 women
SOFA score (ICU admission)7.5 (IQR = 7)
SOFA score (day of protocol)10.0 (IQR = 5)
APACHE-II (ICU admission)23 (IQR = 7)
APACHE-II (day of protocol)23.5 (IQR = 7.0)
PaO2 (mmHg)80 (IQR = 39)
FiO2 (%)80 (IQR = 30)
PaO2/FiO2138 (IQR = 68)
PEEP (cm H2O)10 (IQR = 2)
MAP (mm Hg)75 (IQR = 16)
mPAP (mm Hg)28 (IQR = 7)
Cardiac index (L/min per square metre)3.7 (IQR = 2.6)
IQR: Interquartile range; SOFA: Sequential organ failure assessment; APACHE: Acute physiological and chronic health evaluation; PEEP: Positive end-expiratory pressure; MAP: Mean arterial pressure; mPAP: Mean pulmonary arterial pressure.
Table 2 Hemodynamic parameter variations (n = 15)
iNOEpoprostenolMilrinoneMilrinone + NO
MAP (mmHg)-2.0 (11.0)1.0 (8.0)3.0 (6.0)3.0 (7.0)
HR (bpm)-2.0 (6.0)0.0 (4.0)0.0 (4.0)0.0 (6.0)1
CVP (mmHg)0.0 (1.4)0.0 (4.0)0.0 (1.0)-1.0 (2.0)
PAOP (mmHg)0.0 (3.0)1.0 (4.0)0.0(2.0)-1.0(3.0)
mPAP (mmHg)-2.0 (4.0)-1.0 (3.0)0.0 (3.0)-2.0 (3.0)1
CI (L/min per square metre)0.1 (0.6)0.0 (0.7)0.6 (0.9)-0.1 (0.4)
iPVR-30.6 (130.9)-51.7 (165.2)-9.4 (103.1)0.0 (91.2)
1No hemodynamic variation reached statistical significance (P > 0.1 for any value) except for the median mPAP variations in the Milrinone + NO group (P = 0.47). MAP: Mean arterial pressure; HR: Heart rate; CVP: Central venous pressure; PAOP: Pulmonary artery occlusion pressure; mPAP: Mean pulmonary arterial pressure; CI: Cardiac index; iPVR: Indexed pulmonary vascular resistance; iNO: Inhaled nitric oxide.